TheEdgeResearch
Home / Stocks / EBAC

European Biotech Acquisition Corp. (EBAC)

NASDAQ Financial Services Shell Companies
$11.19 ▼ -4.44%
Market Cap
$183.5M
Sector
Financial Services
Industry
Shell Companies
Beta
0.00
52-Wk Range
9.282-14.1
CEO
Eduardo Bravo Fernandez de Araoz
Country
NL
Currency
USD

European Biotech Acquisition Corp. operates in the Shell Companies industry of the Financial Services sector, headquartered in Amsterdam, NL. The stock last traded at $11.19, down 4.44% on the session, giving a market capitalisation of $183.5M. On trailing twelve-month figures it carries a trailing P/E of 41.44, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
41.44
Price / Sales
0.00
Price / Book
1.18
EV / EBITDA
0.00
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
0.45
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
IPO date
2021-05-11
Headquarters
Amsterdam, NL
About European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (EBAC) is presently not engaged in substantial business operations. Instead, its core purpose is to facilitate a business combination, potentially through a merger, share exchange, asset acquisition, share purchase, or reorganization, with one or more other companies or organizations. The firm was established in 2021 and its headquarters are located in Amsterdam, the Netherlands.

Comparable companies

European Biotech Acquisition Corp. is most often compared with the following Financial Services names:

APCABTWNCONXGSQBPRBMSKGRTRISZPTA
More research on EBAC
EBAC technical analysis EBAC TheEdge Score Compare against peers
Open full interactive analysis & DCF →